XZXuan Zeng

Xuan Zeng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xuan Zeng has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • pH-sensitive MOF integrated with glucose oxidase for glucose-responsive insulin delivery

    by Cheng Zhang, Sheng Hong, Miao-Deng Liu, Wu-Yang Yu, Ming-Kang Zhang, Lu Zhang, Xuan Zeng, Xian-Zheng Zhang


  • Remodeling extracellular matrix based on functional covalent organic framework to enhance tumor photodynamic therapy

    by Shi-Bo Wang, Zhao-Xia Chen, Fan Gao, Cheng Zhang, Mei-Zhen Zou, Jing-Jie Ye, Xuan Zeng, Xian-Zheng Zhang


  • A multi-functional drug delivery system based on polyphenols for efficient tumor inhibition and metastasis prevention

    by Si Chen, Jin-Xuan Fan, Di-Wei Zheng, Fan Liu, Xuan Zeng, Guo-Ping Yan, Xian-Zheng Zhang

    Although chemotherapy is the most common method in clinical therapeutics with a straightforward mechanism, conventional anti-tumor drugs are still almost incapable of preventing the occurrence of tumor metastasis. In this study, we developed a multi-functional drug delivery system EINP@DOX consisting of a tea-derived polyphenol EGCG, iron ions and DOX. The system integrated the functions of tumor inhibition, diagnosis and metastasis prevention to achieve a systematic tumor treatment. The nanoscale size of EINP@DOX facilitated its accumulation in tumor tissues by means of the enhanced permeability and retention (EPR) effect, and it was then transferred to endosomes. The weakly acidic microenvironment in the endosomes of the tumor cells could destroy the coordination structure of EINP@DOX to realize the release of DOX for tumor therapy. Furthermore, the dissociative EGCG played the role of an adjuvant to restrain EMT and down-regulate the MMP levels, which could prevent the occurrence of tumor metastasis. Meanwhile, iron ions as superior magnetic resonance imaging (MRI) contrast agents provided visual evidence for the accurate location of EINP@DOX. In vitro and in vivo studies demonstrated that EINP@DOX showed a remarkable performance in tumor diagnosis and excellent therapeutic efficacy, inhibiting the metastasis of tumor cells effectively at the same time.


  • A modular theranostic platform for tumor therapy and its metabolic studies

    by Ke Li, Jiang-Lan Li, Di-Wei Zheng, Xuan Zeng, Chuan-Jun Liu, Xian-Zheng Zhang

    A novel nanoplatform with pH stimulating benzimidazole and glutathione stimulating ferrocene as stoppers was fabricated. The nanoplatform could be modularized to construct carriers with remarkable theranostic and synergistic antitumor properties.


  • A self-delivery system based on an amphiphilic proapoptotic peptide for tumor targeting therapy

    by Si Chen, Jin-Xuan Fan, Xin-Hua Liu, Ming-Kang Zhang, Fan Liu, Xuan Zeng, Guo-Ping Yan, Xian-Zheng Zhang

    In recent decades, drug self-delivery systems (DSDSs) have appeared with extraordinary superiority for cancer therapy while realizing intracellular delivery without supererogatory drug carriers. Here, we have designed and programmed a novel self-delivery system to realize tumor targeting therapy. The amphiphilic proapoptotic peptide KLAKLAKKLAKLAKGCK(Fmoc)2 (KLA) was used to form a self-assembled structure (KD) by encapsulating the hydrophobic anticarcinogen doxorubicin (DOX). Then, tumor recognizing hyaluronic acid (HA) was coated on the surface of KD to obtain a tumor targeting self-delivery system (KDH). The protective layer of HA could protect the therapeutic agents from being inactivated during blood circulation, and further specifically recognize tumor cells by the CD44 receptor after KDH had located the tumor regions. Additionally, hyaluronidase (HAase) overexpressed in the endosome of tumor cells could degrade the protective layer of HA and accelerate the liberation of KLA and DOX. The proapoptotic peptide KLA had the ability to locate mitochondria and induce mitochondrial dysfunction; meanwhile the anticarcinogen DOX diffused to the nuclei to inhibit the growth of tumor cells. Both in vitro and in vivo studies identified that our self-delivery system KDH possessed precise tumor targeting, and exhibited fantastic antitumor efficacy as well as negligible side effects.


  • A dual-responsive, hyaluronic acid targeted drug delivery system based on hollow mesoporous silica nanoparticles for cancer therapy

    by Lin Huang, Jia Liu, Fan Gao, Qian Cheng, Bo Lu, Hua Zheng, Haixing Xu, Peihu Xu, Xianzheng Zhang, Xuan Zeng

    In this study, a novel drug delivery system (HMSNs-SS-HA) based on hollow mesoporous silica nanoparticles (HMSNs) was developed for delivering anticancer drugs (e.g., doxorubicin (DOX)) to targeted tumour cells by using disulfide bonds as redox-sensitive linkers and hyaluronic acid (HA) molecules as both capping and targeting agents. Well-dispersed HMSNs were synthesized with a dimension of around 100 nm. Detailed physical characterization further demonstrated that HMSNs-SS-HA has been successfully constructed. The in vitro drug release experiments displayed the enzyme and redox dual-responsive and sustained drug release properties of DOX loaded HMSNs-SS-HA. Additionally, a series of biological evaluations indicated that these DOX loaded HMSNs-SS-HA could accurately target murine mammary carcinoma (4T1) cells to induce cell apoptosis in vitro and suppress tumour growth in vivo. These results demonstrated that DOX loaded HMSNs-SS-HA was suitable as a potential and efficient drug delivery nanosystem for cancer therapy.


  • A cellular/intranuclear dual-targeting nanoplatform based on gold nanostar for accurate tumor photothermal therapy

    by Si Chen, Jinxuan Fan, Wenxiu Qiu, Fan Liu, Guoping Yan, Xuan Zeng, Xianzheng Zhang

    In this work, a cellular/intranuclear dual-targeting nanoplatform was designed for tumor photothermal therapy (PTT). As a photo-to-heat nanoheater, a gold nanostar (GNS) was decorated with a nuclear localization sequence (NLS) to form GNS-NLS which possessed nuclear-targeting ability. After that, hyaluronic acid (HA) was coated on the surface of GNS-NLS (GNS-NLS@HA) via electrostatic interaction for tumor cellular recognition and targeting. It was found that by harnessing the recognition of CD44 receptor by HA, GNS-NLS@HA had the ability to target tumor cells accurately, and further be efficaciously internalized into cells with stellate shape. Subsequently, tumor intracellular hyaluronidase (HAase) from the endosome led to the degradation of HA to expose nuclear-targeting nanoheater GNS-NLS, and GNS-NLS was able to enhance PTT efficiency through subcellular nuclear location by a dual-stage near infrared light irradiation strategy. The first stage of light irradiation was of short duration to enhance the subcellular location of the nanoplatform to nuclei, and the second stage of light irradiation was of long duration to achieve admirable photothermal transduction as well as destruction of nuclei. This cellular/intranuclear dual-targeting nanoplatform, GNS-NLS@HA, displayed prominent tumor suppression efficiency both in vitro and in vivo, and inhibited tumor metastasis effectively.


  • Dual Drug Delivery System Based on Biodegradable Organosilica Core–Shell Architectures

    by Jiang-Lan Li, Yin-Jia Cheng, Chi Zhang, Han Cheng, Jun Feng, Ren-Xi Zhuo, Xuan Zeng, Xian-Zheng Zhang

    To overcome drug resistance, efficient cancer therapeutic strategies using a combination of small-molecule drugs and macromolecule drugs is highly desired. However, because of their significant differences in molecular weight and size, it is difficult to load them simultaneously in one vector and to release them individually. Here, a biodegradable organosilica-based core–shell-structured nanocapsule was designed and used as a dual stimuli-responsive drug vector to solve this problem. Biodegradable organosilica shell coated outside the macromolecule model drug “core” would be disrupted by high glutathione (GSH) levels inside tumor cells, resulting in the escape of the entrapped drugs. Small-molecule drugs capping on the surface of the organosilica shell via pH-responsive imine bonds can be cut and released in the acidic lysosomal environment. Transmission electron microscopy has shown that the framework of the organosilica shell was dissolved and degraded after 8 h incubation with 5 mM GSH. Confocal imaging confirmed that small-molecule and macromolecular drugs were individually released from the nanoparticles because of the pH or redox-triggered degradation under the tumor microenvironment and thus led to the strong fluorescence recovery in the cytoplasm. As expected, these biodegradable organosilica nanoparticles could not release drugs into normal cells but could specifically release them into tumor cells owing to their tumor-triggered targeting capability. This system will serve as an efficient shuttle for multidrug delivery and also provide a potential strategy to overcome drug resistance.


  • A redox-responsive mesoporous silica based nanoplatform for in vitro tumor-specific fluorescence imaging and enhanced photodynamic therapy

    by Fan Yuan, Jiang-Lan Li, Han Cheng, Xuan Zeng, Xian-Zheng Zhang

    A mesoporous silica nanoparticle-based redox-responsive platform modified with multifunctional peptides was successfully developed for in vitro tumor microenvironment-enhanced photodynamic therapy.


  • Multifunctional Peptide-Amphiphile End-Capped Mesoporous Silica Nanoparticles for Tumor Targeting Drug Delivery

    by Yin-Jia Cheng, Ai-Qing Zhang, Jing-Jing Hu, Feng He, Xuan Zeng, Xian-Zheng Zhang

    A tumor targeting redox-responsive drug delivery system (DDS) with bioactive surface was constructed by immobilizing peptide-based amphiphile C12-CGRKKRRQRRRPPQRGDS (defined as ADDA-TCPP) onto the mesoporous silica nanoparticles (MSNs) as an end-capping nanovalve, which consists of two main segments: a hydrophobic alkyl chain ADDA and a hydrophilic amino acid sequence containing a Tat48-60 peptide sequence with a thiol terminal group and an RGDS targeting ligand, via a disulfide linkage for redox-triggered intracellular drug delivery. A series of characterizations confirmed that the nanosystem had been successfully fabricated. The antitumor drug doxorubicin (DOX) was selected as a model drug and efficiently trapped in the pores of MSNs, and an in vitro release experiment demonstrated that the mesopores of the resulting DOX-loaded MSNs (DOX@MSN-ss-ADDA-TCPP) could be sealed tightly with ADDA-TCPP self-assemblies through hydrophobic interactions between the alkyl chains; the resulting DDS exhibited “zero premature release” of DOX in the physical environment. However, a burst drug release was triggered by a high concentration of glutathione (GSH) in simulated cellular cytosol. Moreover, detailed investigations confirmed that incorporation of RGDS peptide facilitated the active targeting delivery of DOX to αvβ3 integrin overexpressed tumor cells, and Tat48-60 modification on MSNs could enhance intracellular drug delivery, exhibiting an obvious toxicity to tumor cells. The multifunctional nanosystem constructed here can realize the controlled drug release and serve as a platform for designing multifunctional nanocarriers using diversified bioactive peptide-based amphiphile.